FGF-21 as a Potential Biomarker for Mitochondrial Diseases

Author(s): Leila Motlagh Scholle*, Diana Lehmann, Marcus Deschauer, Torsten Kraya, Stephan Zierz.

Journal Name: Current Medicinal Chemistry

Volume 25 , Issue 18 , 2018

  Journal Home
Translate in Chinese


The diagnosis of mitochondrial diseases is still challenging due to clinical and genetical heterogeneity. The development of advanced technologies including Whole-Exome- Sequencing (WES) and Whole-Genome-Sequencing (WGS) has led to improvements in genetic diagnosis. However, a reliable biomarker in serum could enhance and ease the diagnosis and indeed reduce the need for muscle biopsy. Several studies suggest Fibroblast growth factor 21 (FGF-21) as a biomarker for diagnosis in mitochondrial disorders. It is known, that in patients with mitochondrial disorders, the expression of FGF-21 gets elevated in an effort to counteract the underlying metabolic deficiency. The growth and differentiation factor 15 (GDF-15) has been described as a potential biomarker for mitochondrial diseases, too. In the present review, a literature research, using PubMed database about the reliability of FGF-21 as a biomarker for mitochondrial disorders and its comparison with GDF-15 has been performed.

Keywords: FGF-21, Mitochondrial diseases, biomarker, GDF-15, COX, diagnosis.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [2070 - 2081]
Pages: 12
DOI: 10.2174/0929867325666180111094336
Price: $58

Article Metrics

PDF: 54
HTML: 13
PRC: 2